<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医麦客 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-10T11:16:51+08:00</updated>
  <subtitle>医麦客是一个聚焦转化医学、精准医疗和生物制药的专业媒体平台，持续关注体外诊断、抗体药物、细胞治疗、基因治疗等细分领域。为新生物医药医疗领域的企业发声，推动企业和行业的快速发展。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>AAV基因治疗罕见遗传病潜力巨大，临床研究显示疗效积极丨医麦猛爆料</title>
    <updated>2020-12-10T07:41:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/iL31qKzKjEfb8jPaIPiToA</id>
    <link href="https://mp.weixin.qq.com/s/iL31qKzKjEfb8jPaIPiToA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>ASH 2020：北恒生物公布通用型CAR-T产品CTA101治疗复发性或难治性B细胞急性淋巴细胞白血病研究数据</title>
    <updated>2020-12-10T07:41:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/n-I0d8gKsMCjFqgF5BDgRA</id>
    <link href="https://mp.weixin.qq.com/s/n-I0d8gKsMCjFqgF5BDgRA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球首款！华龛生物3D微载体产品获得CDE药用辅料资质丨医麦猛爆料</title>
    <updated>2020-12-10T07:41:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/sItsuYmY_ybwGlOVt2aEtA</id>
    <link href="https://mp.weixin.qq.com/s/sItsuYmY_ybwGlOVt2aEtA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>又一款ADC药物申报临床！和元生物旗下子公司的DR5 ADC临床申请获得受理丨医麦猛爆料</title>
    <updated>2020-12-10T07:41:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/soCS4uit8J3bYOTRdvXNTw</id>
    <link href="https://mp.weixin.qq.com/s/soCS4uit8J3bYOTRdvXNTw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>随着国家对人类遗传资源的监管力度加大，生物医药企业如何从容应对人类遗传资源监管及最新注册法规丨医麦猛爆料</title>
    <updated>2020-12-10T07:41:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/mAtfJxBxPH1ZT_DjD3Dv3g</id>
    <link href="https://mp.weixin.qq.com/s/mAtfJxBxPH1ZT_DjD3Dv3g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>张会来教授：霍奇金淋巴瘤的未来治疗趋势是传统治疗与靶向治疗的结合</title>
    <updated>2020-12-10T07:41:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/f2EncT_hwIkh8Y7eycZgbw</id>
    <link href="https://mp.weixin.qq.com/s/f2EncT_hwIkh8Y7eycZgbw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>「峰客访谈」新格元生物副总裁訾晓渊：单细胞测序，下一代遗传学上的显微镜</title>
    <updated>2020-12-10T07:41:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/H0c8lDfQUFtcn7bVNtaPwg</id>
    <link href="https://mp.weixin.qq.com/s/H0c8lDfQUFtcn7bVNtaPwg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>细胞治疗产业蓬勃发展，需要更加可靠、高效和灵活的生产管理平台丨医麦新观察</title>
    <updated>2020-12-09T09:06:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/Ve-w7hq-oQB8aYe3TD1ZLQ</id>
    <link href="https://mp.weixin.qq.com/s/Ve-w7hq-oQB8aYe3TD1ZLQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>邀请函 | 2020年创新药物临床前研究学术研讨会</title>
    <updated>2020-12-09T09:06:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/1Yq5zqQigEfR9EnByo0r6Q</id>
    <link href="https://mp.weixin.qq.com/s/1Yq5zqQigEfR9EnByo0r6Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>东曜药业公布ADC在研药物TAA013 I期研究结果丨医麦猛爆料</title>
    <updated>2020-12-09T09:06:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/QvkEPDdd_33iubRmqoITnA</id>
    <link href="https://mp.weixin.qq.com/s/QvkEPDdd_33iubRmqoITnA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>复盘ASH2020：聚焦BCMA CAR-T，自体、同种异体、非病毒载体、双靶点齐上阵丨医麦新观察</title>
    <updated>2020-12-09T09:06:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/ha_MKgXUqbwY5GdWA_BAPw</id>
    <link href="https://mp.weixin.qq.com/s/ha_MKgXUqbwY5GdWA_BAPw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>最后两天优惠丨人类遗传资源与生物医药注册法规官方解读</title>
    <updated>2020-12-09T09:06:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/M_Yuz1bp_iDmL-YZ2cRwCg</id>
    <link href="https://mp.weixin.qq.com/s/M_Yuz1bp_iDmL-YZ2cRwCg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>高力教授：ASCT治疗T细胞淋巴瘤（新桥）经验分享</title>
    <updated>2020-12-09T09:06:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/XgYY3HVNe9zvrcgSKw5wPg</id>
    <link href="https://mp.weixin.qq.com/s/XgYY3HVNe9zvrcgSKw5wPg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>「峰客访谈」予果生物CEO夏涵：与时间、市场赛跑，抢夺mNGS领域排头兵</title>
    <updated>2020-12-09T09:06:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/Fgt2S52lGLTHPRufBOMILg</id>
    <link href="https://mp.weixin.qq.com/s/Fgt2S52lGLTHPRufBOMILg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>聚焦ASH 2020：ROR1 ADC赛道有何看点？丨医麦新观察</title>
    <updated>2020-12-07T23:57:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/Grwgqk_X83trRxwYQl46sw</id>
    <link href="https://mp.weixin.qq.com/s/Grwgqk_X83trRxwYQl46sw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>科济生物BCMA CAR-T疗法正式纳入突破性治疗品种，ASH年会最新数据展现治疗R/R MM患者的巨大潜力丨医麦猛爆料</title>
    <updated>2020-12-07T23:57:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/77jx-8pbgMw0moD_8xmYqg</id>
    <link href="https://mp.weixin.qq.com/s/77jx-8pbgMw0moD_8xmYqg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>920医院及新桥医院联合开展世界首例通用型CAR-T细胞治疗成人急性T淋巴细胞白血病丨医麦猛爆料</title>
    <updated>2020-12-07T23:57:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/0yVcBBBF6ZbdwGajxjzlhg</id>
    <link href="https://mp.weixin.qq.com/s/0yVcBBBF6ZbdwGajxjzlhg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>ASH 2020：再生元CD20/CD3双抗显示出积极的临床数据，以CAR-T细胞为潜在竞争对手丨医麦猛爆料</title>
    <updated>2020-12-07T23:57:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/Wwb5ZlLYRaMM9c-zC0fVPw</id>
    <link href="https://mp.weixin.qq.com/s/Wwb5ZlLYRaMM9c-zC0fVPw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>ASH 2020：亚盛医药公布抗耐药白血病新药HQP1351（奥瑞巴替尼）关键性注册II期研究的积极数据</title>
    <updated>2020-12-07T23:57:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/Jeg4WBJ3ws9hMjU5z4w5lQ</id>
    <link href="https://mp.weixin.qq.com/s/Jeg4WBJ3ws9hMjU5z4w5lQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>梁爱斌教授：CAR-T细胞治疗血液肿瘤日趋成熟，临床研究及应用的规范性和科学性有待加强</title>
    <updated>2020-12-07T23:57:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/NtcTw21sVDkCo5dyBvlrng</id>
    <link href="https://mp.weixin.qq.com/s/NtcTw21sVDkCo5dyBvlrng" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>